CA2938592A1 - Methods for treating fibrotic disease - Google Patents

Methods for treating fibrotic disease Download PDF

Info

Publication number
CA2938592A1
CA2938592A1 CA2938592A CA2938592A CA2938592A1 CA 2938592 A1 CA2938592 A1 CA 2938592A1 CA 2938592 A CA2938592 A CA 2938592A CA 2938592 A CA2938592 A CA 2938592A CA 2938592 A1 CA2938592 A1 CA 2938592A1
Authority
CA
Canada
Prior art keywords
modulator
combination
fibrosis
genes
translational
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2938592A
Other languages
English (en)
French (fr)
Inventor
James Appleman
Peggy A. Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Effector Therapeutics Inc
Original Assignee
Effector Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effector Therapeutics Inc filed Critical Effector Therapeutics Inc
Publication of CA2938592A1 publication Critical patent/CA2938592A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
CA2938592A 2014-02-07 2015-02-07 Methods for treating fibrotic disease Abandoned CA2938592A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461937272P 2014-02-07 2014-02-07
US61/937,272 2014-02-07
US201462010004P 2014-06-10 2014-06-10
US62/010,004 2014-06-10
US201462037497P 2014-08-14 2014-08-14
US62/037,497 2014-08-14
PCT/US2015/014939 WO2015120350A2 (en) 2014-02-07 2015-02-07 Compositions and methods for treating fibrotic disease

Publications (1)

Publication Number Publication Date
CA2938592A1 true CA2938592A1 (en) 2015-08-13

Family

ID=52684645

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2938592A Abandoned CA2938592A1 (en) 2014-02-07 2015-02-07 Methods for treating fibrotic disease

Country Status (7)

Country Link
US (2) US9993494B2 (enExample)
EP (1) EP3102703A2 (enExample)
JP (1) JP2017510552A (enExample)
CN (1) CN106102775A (enExample)
AU (1) AU2015213721B2 (enExample)
CA (1) CA2938592A1 (enExample)
WO (1) WO2015120350A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US11026945B2 (en) * 2016-04-29 2021-06-08 The Trustees Of The University Of Pennsylvania Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation
US10894960B2 (en) 2016-08-30 2021-01-19 Children's Hospital Medical Center Compositions and methods for nucleic acid transfer
WO2018055578A1 (en) 2016-09-22 2018-03-29 The University Of Hong Kong Preventive and therapeutic approach for aberrant cell differentiation and isr-associated diseases
WO2018149978A1 (en) * 2017-02-16 2018-08-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. ALTERNATIVE ACTIVATION OF MACROPHAGES (M2 CELLS) THROUGH THE POLYAMINE-eIF5a-HYPUSINE AXIS
US12411144B2 (en) 2017-03-22 2025-09-09 Children's Hospital Medical Center Compositions and methods for treatment of lung function
CN106983738B (zh) * 2017-04-13 2020-03-10 深圳市润佳通科技有限公司 甲状腺激素及其药学上可接受的盐或前药在制备治疗和/或预防皮肤疾病的药物中的应用
KR102641269B1 (ko) * 2017-05-24 2024-02-26 이펙터 테라퓨틱스, 인크. 개선된 항종양 면역 반응을 위한 조성물 및 방법
CN107260730B (zh) * 2017-05-31 2019-10-22 上海市东方医院 组蛋白去乙酰化酶hdac6的抑制剂在制备防治腹膜透析后腹膜纤维化的药物中的用途
PL3658141T3 (pl) 2017-07-24 2023-06-12 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Leczenie stanów patologicznych przez bezpośrednie i pośrednie celowanie w oddziaływanie sirpalfa - cd47
EA202090393A1 (ru) 2017-07-28 2020-05-20 Кёрин Фармасьютикал Ко., Лтд. Терапевтическое средство от фиброза
CN107326093B (zh) * 2017-09-04 2020-01-21 东南大学 基于Taqman探针的慢性肾脏病相关基因检测荧光定量PCR一步法试剂盒及其应用
CN107916254B (zh) * 2017-11-29 2020-05-12 武汉大学 Homer1单克隆抗体及其应用
CN108192984B (zh) * 2018-02-13 2020-06-23 浙江大学 与湖羊肉质性状相关的分子标记及特异性引物对和应用
WO2019180664A1 (en) * 2018-03-21 2019-09-26 The University Of Hong Kong Method for preventing or modulating fibrosis and fibrotic response associated with the integrated stress response
AU2020299362A1 (en) 2019-07-02 2022-02-24 Effector Therapeutics, Inc. EiF4e-inhibiting 4-OXO-3,4-dihydropyrido(3,4-d)pyrimidine compounds
KR102100163B1 (ko) * 2019-09-24 2020-04-13 테고사이언스 (주) 켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물
CN111228464A (zh) * 2020-02-28 2020-06-05 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 广谱抗冠状病毒的多肽及其用途
CN113679841A (zh) * 2020-05-19 2021-11-23 上海市同济医院 一种磷脂酶d1(pld1)基因及其抑制剂在肝纤维化防治中的应用
US20230181582A1 (en) 2020-05-22 2023-06-15 Qx Therapeutics Inc. Compositions and methods for treating lung injuries associated with viral infections
WO2021243319A1 (en) * 2020-05-29 2021-12-02 Novomedix, Llc Biarylsulfonamides and pharmaceutical compositions thereof, and their use for treating fibrotic lung disease
US20230374591A1 (en) * 2020-10-08 2023-11-23 The Trustees Of Dartmouth College Methods and agents for treating, preventing, diagnosing, and evaluating therapy for fibrotic, autoimmune, and inflammatory conditions
US20240066021A1 (en) * 2021-01-15 2024-02-29 Children's Hospital Medical Center Methods for optimizing cftr-modulator therapy
GB202109534D0 (en) * 2021-07-01 2021-08-18 Anglia Ruskin Univ Higher Education Corporation Treatment of scarring
EP4374868A4 (en) * 2021-07-22 2025-08-06 Shanghai Synvida Biotechnology Co Ltd PHARMACEUTICAL COMPOSITION OR MEDICINE KIT FOR RELIEVING OR TREATING FIBROTIC DISEASES, AND ITS USE
CN118804976A (zh) * 2021-12-17 2024-10-18 雷杰纳荣制药公司 用整联蛋白亚基α1(ITGA1)抑制剂治疗肺部疾患
CN115558712A (zh) * 2022-09-22 2023-01-03 华中科技大学同济医学院附属协和医院 Fam177a1的新用途
WO2025092340A1 (zh) * 2023-11-03 2025-05-08 成都嘉葆药银医药科技有限公司 吡咯并三嗪类化合物在制备预防和/或治疗纤维化或其相关疾病的药物中的应用
CN117589999A (zh) * 2023-11-17 2024-02-23 深圳市人民医院 Pfkp作为慢性肾脏疾病治疗靶点的应用及其抑制剂
CN120789266A (zh) * 2025-09-10 2025-10-17 山东第一医科大学第一附属医院(山东省千佛山医院) Eif3a抑制剂在制备治疗肝纤维化药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046219A (en) 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
EP1693059A1 (en) 2005-02-22 2006-08-23 Deutsches Krebsforschungszentrum Use of rocaglamide derivatives as NF-AT-specific inhibitors for the treatment of certain inflammatory diseases
JP4512828B2 (ja) 2005-04-12 2010-07-28 国立大学法人 千葉大学 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット
WO2007027509A2 (en) * 2005-08-31 2007-03-08 Biogen Idec Ma Inc. Evaluating and treating scleroderma
GB0617117D0 (en) 2006-08-31 2006-10-11 Renovo Ltd Method of diagnosis
US20090004668A1 (en) * 2007-06-22 2009-01-01 The Board Of Trustees Of The Leland Stanford Junior University Pre-miRNA loop-modulated target regulation
US7550300B1 (en) 2007-11-29 2009-06-23 Capgen Sciences, Inc. Prediction of bare metal stent restenosis
CA2742298C (en) 2008-11-03 2019-09-10 The Regents Of The University Of California Methods for detecting modification resistant nucleic acids
AU2009321723A1 (en) 2008-12-05 2010-06-10 Intermed Discovery Gmbh Inhibitors of HIF-1 protein accumulation
US20100152531A1 (en) * 2008-12-11 2010-06-17 Paracor Medical, Inc. Implantable medical device for drug delivery and method of use
WO2010080248A2 (en) 2008-12-18 2010-07-15 The Board Of Regents Of The University Of Texas System Peptides that bind eukaryotic translation initiation factor 4e
CN102640001A (zh) 2009-11-05 2012-08-15 诺瓦提斯公司 预测纤维化进展的生物标记物
FR2954943B1 (fr) * 2010-01-07 2013-03-01 Sanofi Aventis Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
WO2011140334A2 (en) 2010-05-06 2011-11-10 Trustees Of Boston University Compounds, methods of making or identifying compounds, and uses thereof
EP2576532B1 (en) 2010-06-07 2018-07-18 Novomedix, LLC Furanyl compounds and the use thereof
JP2013533258A (ja) 2010-06-28 2013-08-22 プレジデント アンド フェローズ オブ ハーバード カレッジ 細胞増殖を阻害するための化合物
US9156781B2 (en) 2012-11-30 2015-10-13 Novomedix, Llc Substituted biaryl sulfonamides and the use thereof
US20140243356A1 (en) 2013-02-07 2014-08-28 The Regents Of The University Of California Use of translational profiling to identify target molecules for therapeutic treatment
WO2014124412A2 (en) 2013-02-11 2014-08-14 President And Fellows Of Harvard College Methods and compounds for the inhibition of cellular proliferation

Also Published As

Publication number Publication date
US20150224132A1 (en) 2015-08-13
WO2015120350A2 (en) 2015-08-13
JP2017510552A (ja) 2017-04-13
AU2015213721A1 (en) 2016-07-28
WO2015120350A3 (en) 2015-10-01
AU2015213721B2 (en) 2021-05-20
CN106102775A (zh) 2016-11-09
US9993494B2 (en) 2018-06-12
US10576098B2 (en) 2020-03-03
US20190038657A1 (en) 2019-02-07
EP3102703A2 (en) 2016-12-14

Similar Documents

Publication Publication Date Title
US10576098B2 (en) Compositions and methods for treating fibrotic disease
Gulati et al. The aging lung and idiopathic pulmonary fibrosis
Lietman et al. Inhibition of Wnt/β-catenin signaling ameliorates osteoarthritis in a murine model of experimental osteoarthritis
Wan et al. Autophagy promotes osteogenic differentiation of human bone marrow mesenchymal stem cell derived from osteoporotic vertebrae
Schmidt et al. Genetic predisposition to kidney cancer
Zhao et al. Targeting of discoidin domain receptor 2 (DDR2) prevents myofibroblast activation and neovessel formation during pulmonary fibrosis
Yu et al. Serum amyloid A, an acute phase protein, stimulates proliferative and proinflammatory responses of keratinocytes
Zhang et al. Hedgehog signaling controls bone homeostasis by regulating osteogenic/adipogenic fate of skeletal stem/progenitor cells in mice
JP2017510552A5 (enExample)
US20140288097A1 (en) Use of translational profiling to identify target molecules for therapeutic treatment
EP3421035A1 (en) Novel use of chromone derivative as pharmaceutical composition for preventing and treating fibrosis by using epithelial-mesenchymal transition inhibitory activity thereof
Zheng et al. Expression of HMGB1 in septic serum induces vascular endothelial hyperpermeability
Zhu et al. Down‐regulation of Rac GTPase‐activating protein OCRL1 causes aberrant activation of Rac1 in osteoarthritis development
Sultana et al. Snx10 and PIKfyve are required for lysosome formation in osteoclasts
Alenchery et al. PAI‐1 mediates TGF‐β1‐induced myofibroblast activation in tenocytes via mTOR signaling
EP2941270B1 (en) Methods for treating inflammation
JP2019519514A (ja) 概日時計の乱れに関連するマイクロバイオームの調節異常を処置するための方法及び医薬組成物
Gu et al. Histone deacetylase 1 and 3 inhibitors alleviate colon inflammation by inhibiting Th17 cell differentiation
Rabiee Motmaen et al. Acidic pH derived from cancer cells as a double‐edged knife modulates wound healing through DNA repair genes and autophagy
Pan et al. RNF2 mediates pulmonary fibroblasts activation and proliferation by regulating mTOR and p16-CDK4-Rb1 signaling pathway
Takeuchi et al. Kruppel-like factor 4 upregulates matrix metalloproteinase 13 expression in chondrocytes via mRNA stabilization
US11369609B2 (en) Small molecule Wnt inhibitor as treatment for dyslipidemia
Jiang et al. Raspberry ketone alleviates radiation-induced lung injury through the STAT2-P2X7r/NLRP3 signaling pathway
US20090054316A1 (en) Agent for control of function of antigen-presenting cell
Wilson et al. Critical role for the TGF-β1/mTORC1 signalling axis in defining the transcriptional identity of CTHRC1+ pathologic fibroblasts

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831

FZDE Discontinued

Effective date: 20210831